Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
TransAlta Enters Memorandum of Understanding for Data Centre Development at Keephills Site with Potential to Scale Up to 1 GW
-
TransAlta to Host Investor Day
-
TransAlta Reports Fourth Quarter and Year End 2025 Results, Announces Data Centre Agreement, Declares Dividend Increase and Provides 2026 Outlook
-
OrthoPediatrics to Participate in Upcoming Conferences
-
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results
-
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
-
Brunswick Exploration Announces Appointment of Vice President – International Projects
-
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
-
Brunswick Exploration Files Maiden Mineral Resource Estimate NI 43-101 Technical Report for Mirage Project
-
ADARx Pharmaceuticals Presents Onvuzosiran Data Supporting Potential for Sustained Attack-Free Rates with Reduced Treatment Burden in Patients with HAE
-
Range Increases Quarterly Dividend By 11%
-
Boralex and Six Nations of the Grand River Development Corporation Commission Canada’s Largest Operating Battery Storage Facility
-
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
-
Flare Therapeutics Presents Updated FX-909 Phase 1A Data in Late-Breaking Oral Presentation at 2026 ASCO Genitourinary Cancers Symposium
-
Aurora Mobile Partners with China Post Securities to Deliver Millisecond Messaging and Enhance Digital Financial Services
-
Enwex Netherlands, France and Spain Wind Futures Now Live for Trading on Abaxx Exchange
-
Gogo Announces Fourth Quarter and Full Year 2025 Results
-
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
-
Notice of the Annual General Meeting of Orrön Energy AB
-
OTC Markets Group Welcomes RUA GOLD INC. to OTCQX
-
Zoomcar Announces Launch of Offer to Exchange Outstanding Warrants for Common Stock
-
YieldMax® Introduces Portfolio Option Income Strategy ETF on Strategic Metals & Mining (MINY)
-
Natural Resource Partners L.P. Reports Fourth Quarter and Full Year 2025 Results and Announces Special Distribution
-
Endeavour Silver Announces Q4 2025 Financial Results; Earnings Call at 10AM PST (1PM EST) Today
-
ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
-
SourceDay Named to The Hackett Group’s 2025–2026 50 to Know List
-
Stacey Caywood has officially assumed the role of CEO at Wolters Kluwer
-
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
-
Xmarket Launches Beta on BNB Chain Mainnet:
-
Jura Provides Disclosure Regarding Shareholder Claim by PEL’s CEO
-
Banco Itaú Chile Announces Fourth Quarter 2025 Management Commentary
-
Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma
-
Pro Kapital Council approved Consolidated Interim Report for IV Quarter and 12 Months of 2025 (Unaudited)
-
Man Group PLC : Form 8.3 - LondonMetric Property Plc
-
Man Group PLC : Form 8.3 - Beazley Plc
-
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
-
Johnson Outdoors Announces Cash Dividend
-
BrightSpring Health Services, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
-
Nominal Accelerates Naval Aviation Testing and Validation for Future Collaborative Combat Aircraft
-
Total Voting Rights
-
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
-
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
-
Dimensional Fund Advisors Ltd. : Form 8.3 - SPIRE HEALTHCARE GROUP PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - PICTON PROPERTY INCOME LTD - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - NCC GROUP PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - LIFE SCIENCE REIT PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - JUST GROUP PLC - Ordinary Shares
-
CORRECTION: Eesti Energia Group Unaudited Results for 2025
-
The Luxury Report announces the winners of their 2025 awards
-
Bekaert achieves ISCC PLUS certification for steel tire reinforcement, pioneering certified materials in the tire industry
